Amicus Therapeutics, Inc. (NASDAQ:FOLD) Receives $16.75 Average Price Target from Analysts
Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD – Get Free Report) have earned a consensus recommendation of “Moderate Buy” from the nine research firms that are currently covering the firm, Marketbeat reports. Two analysts have rated the stock with a hold recommendation and seven have assigned a buy recommendation to the company. The average 1-year price […]
Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD – Get Free Report) have earned a consensus recommendation of “Moderate Buy” from the nine research firms that are currently covering the firm, Marketbeat reports. Two analysts have rated the stock with a hold recommendation and seven have assigned a buy recommendation to the company. The average 1-year price […]
